News

Read our latest news, and find more about us and our portfolio companies.

2018/03/16
Lundbeck to acquire Prexton Therapeutics adding foliglurax in clinical phase II to its pipeline of innovative treatments for patients suffering from Parkinson's disease

"The sale of Prexton Therapeutics to Lundbeck is a very strong validation of our model of founding companies based on spinning-off assets from Merck KGaA, Darmstadt, Germany and managing them very actively as a shareholder. We are very excited to see the program being acquired by Lundbeck, a leading company in the field of neurology, and feel this is a strong confirmation of the investment thesis on which Prexton was founded in 2012 by Francois Conquet and us, namely that modulating mGluR4 is a highly promising therapeutic approach for the sympomatic treatment of Parkinson`s Disease and dyskinesia.", said Jasper Bos, Ph.D., Vice-President and Head of Healthcare of M Ventures, the corporate venture arm of Merck KGaA, Darmstadt, Germany, Board Member of Prexton.